Study guide

9.4 Pharmacoeconomics & Formulary Decision Making

DHA Pharmacist Licensing Assessment PHO5481

Track your progress as you read

Finished sections get a check mark.

1 Exam Overview & Licensing Pathway

1.1 Current Exam Facts & Format 1.2 Eligibility, PQR & the Sheryan Application Process 1.3 Study Strategy & Test-Day Plan

2 Cardiovascular Pharmacology

2.1 Antihypertensives & RAAS Agents 2.2 Heart Failure & Antiarrhythmic Drugs 2.3 Lipid-Lowering & Antianginal Agents

3 Endocrine & Metabolic Pharmacology

3.1 Insulin & Oral Antidiabetic Agents 3.2 Thyroid, Bone & Calcium Agents 3.3 Corticosteroids & Other Hormonal Agents

4 Anti-Infective Pharmacology

4.1 Beta-Lactam Antibiotics 4.2 Non-Beta-Lactam Antibacterials 4.3 Antifungals, Antivirals & Antituberculars

5 CNS, Psychiatric & Pain Pharmacology

5.1 Psychiatric Pharmacology 5.2 Antiepileptics & Neurologic Agents 5.3 Analgesics: NSAIDs, Opioids & Migraine

6 Respiratory, GI & Hematology Pharmacology

6.1 Respiratory Pharmacology 6.2 Gastrointestinal Pharmacology 6.3 Anticoagulants, Antiplatelets & Hematology Agents

7 Pharmaceutical Care: Cardiometabolic Disease

7.1 Diabetes Management & Counseling 7.2 Hypertension & Dyslipidemia Management 7.3 Heart Failure & Anticoagulation Management

8 Pharmaceutical Care: Respiratory, Rheumatology & Infection

8.1 Asthma & COPD Management 8.2 Gout, Pain & Rheumatologic Care 8.3 Infection Management & Antimicrobial Stewardship

9 Counseling, Monitoring & Special Populations

9.1 Patient Counseling, Adherence & Health Literacy 9.2 Therapeutic Monitoring & Laboratory Interpretation 9.3 Pregnancy, Pediatrics, Geriatrics & Organ Impairment 9.4 Pharmacoeconomics & Formulary Decision Making

10 Pharmaceutical Calculations I

10.1 Concentration, Ratio & Percentage Strength 10.2 Weight-Based & BSA Dosing 10.3 Dilution, Concentration & Alligation

11 Pharmaceutical Calculations II

11.1 Infusion Rates & IV Flow Calculations 11.2 Dispensing Quantities & Days' Supply 11.3 Compounding Calculations, Isotonicity & Milliequivalents

12 UAE Pharmacy Law & Regulation

12.1 UAE Regulatory Framework & Licensing Authorities 12.2 Medicine Registration, Pricing & Supply Chain 12.3 Prescription Requirements & Validity

13 Controlled Drugs, Ethics & Pharmacovigilance

13.1 Controlled & Semi-Controlled Medicines in the UAE 13.2 Ethics, Confidentiality & Generic Substitution 13.3 Pharmacovigilance, Recall & Medicine Disposal

14 Pharmacokinetics I: ADME

14.1 Absorption & Bioavailability 14.2 Distribution & Protein Binding 14.3 Metabolism & Elimination

15 Pharmacokinetics II: Kinetics, Dosing & TDM

15.1 Half-Life, Clearance & Kinetic Order 15.2 Loading & Maintenance Dosing 15.3 Therapeutic Drug Monitoring

16 OTC Medicines & Self-Care

16.1 Cough, Cold & Allergic Rhinitis 16.2 GI Self-Care: Heartburn, Constipation & Diarrhoea 16.3 Pain & Fever Self-Care 16.4 Referral Red Flags, Emergency Contraception & Skin

17 Medication Safety

17.1 High-Alert Medications & Error-Prone Abbreviations 17.2 Medication Reconciliation & Duplicate Therapy 17.3 Adverse Drug Reactions & Hypersensitivity Recognition

18 Sterile & Nonsterile Compounding

18.1 Aseptic Technique & Compounding Environments 18.2 Parenteral, TPN & Cytotoxic Preparation 18.3 Nonsterile Compounding

19 Pharmaceutics, Biopharmaceutics & Toxicology

19.1 Dosage Form Design & the Biopharmaceutics Classification System 19.2 Dissolution & Excipients 19.3 Toxicology: Poisoning Recognition & Antidotes

20 Infection Control, Natural Products, Medicinal Chemistry & Pharmacogenomics

20.1 Infection Control & Immunization 20.2 Pharmacognosy & Dietary Supplements 20.3 Medicinal Chemistry Essentials 20.4 Clinical Pharmacogenomics

9.4 Pharmacoeconomics & Formulary Decision Making

Key Takeaways Explain This Topic AI

Cost-minimisation assumes equivalent outcomes, cost-effectiveness measures them in natural clinical units, cost-utility in QALYs, and cost-benefit in money - identify the analysis from the unit the outcome is expressed in

ICER = (cost of A minus cost of B) divided by (effect of A minus effect of B), and it only becomes a decision when compared with the payer's willingness-to-pay threshold

A therapy that is both cheaper and more effective is dominant and needs no ICER; one that is dearer and less effective is dominated and is rejected

Costs counted depend on perspective: an insurer counts only the direct medical costs it reimburses, while a societal analysis adds direct non-medical, indirect productivity and intangible costs

Generic substitution is a cost-minimisation decision that is valid only where bioequivalence holds, which is why narrow-therapeutic-index medicines are excluded from routine switching

Last updated: August 2026

Why the Exam Tests Pharmacoeconomics

The DHA CBT Guideline names Karen Rascati, Essentials of Pharmacoeconomics among the official reference texts for PHO5481. No content-area bullet is called "pharmacoeconomics", so the material surfaces inside Pharmaceutical Care and Disease State Management : formulary choices, generic substitution decisions, and justifying a therapy to a payer. In UAE community and hospital practice this is daily work - most patients are covered by mandatory health insurance (DHA's scheme in Dubai), formularies are insurer-specific, and the pharmacist is usually the person who has to reconcile a prescriber's choice with what the plan will fund.

Exam items here are conceptual, not computational. You are asked to name the analysis that fits a scenario, read a simple cost-effectiveness comparison, or identify which perspective a stated cost belongs to.

The Four Core Analyses

All four compare costs (always in money) against consequences ; they differ only in how the consequences are measured.

Analysis Consequences measured in Result expressed as Use it when

Cost-minimisation (CMA) Assumed equivalent - not measured Lowest cost wins Outcomes are genuinely equal, e.g. two bioequivalent generic atorvastatins

Cost-effectiveness (CEA) Natural clinical units (mmHg lowered, mmol/L of HbA1c, life-years gained) Cost per unit of effect Comparing two drugs for the same condition with the same outcome measure

Cost-utility (CUA) Quality-adjusted life-years (QALYs) - length adjusted for quality Cost per QALY Comparing across different conditions, or when quality of life matters as much as survival

Cost-benefit (CBA) Money Net benefit or benefit-to-cost ratio Comparing a health programme with a non-health investment

The distinguishing question in an exam stem is always what unit is the outcome in? Money on both sides means CBA. QALYs mean CUA. A clinical unit means CEA. "Assume the outcomes are identical" means CMA - and CMA is only legitimate when that equivalence has actually been demonstrated, which is why it is the correct analysis for a generic-substitution decision and the wrong one for comparing two different drug classes.

Reading an ICER

The incremental cost-effectiveness ratio (ICER) is the single calculation you should be able to do:

ICER = (Cost of A - Cost of B) / (Effect of A - Effect of B)

Worked example. A new anticoagulant costs AED 4,800 per patient-year and prevents 0.030 strokes per year. Warfarin plus INR monitoring costs AED 1,200 per patient-year and prevents 0.018 strokes per year.

  • Incremental cost = 4,800 - 1,200 = AED 3,600
  • Incremental effect = 0.030 - 0.018 = 0.012 strokes prevented
  • ICER = 3,600 / 0.012 = AED 300,000 per stroke prevented

The number is meaningless on its own. It becomes a decision only against a willingness-to-pay threshold set by the payer, and against the cost of the strokes avoided. A therapy that is both cheaper and more effective is dominant and needs no ICER at all; one that is dearer and less effective is dominated and is rejected outright.

Cost Categories and Perspective

Which costs count depends entirely on whose books you are looking at - and stating the perspective is the first thing a well-posed pharmacoeconomic question does.

Direct medical costs : the drug, the dispensing fee, the INR clinic visit, the hospital bed for a bleed.

Direct non-medical costs : the patient's taxi to the anticoagulation clinic, a carer's parking.

Indirect costs : productivity lost while the patient is off work.

Intangible costs : pain, anxiety, reduced quality of life - real, but hard to price, which is why CUA captures them through QALYs instead.

From an insurer's perspective only direct medical costs it reimburses count. From a societal perspective all four count, which is why a drug that looks expensive to a payer can be cost-saving to society once lost working days are included. A stem that says "from the perspective of the health insurer" is telling you to ignore the productivity figures it also supplies - a standard distractor.

The Pharmacist's Practical Role

Generic substitution is the highest-volume pharmacoeconomic act in a UAE pharmacy. It is a cost-minimisation decision, and it is only valid where bioequivalence holds - which is exactly why narrow-therapeutic-index products such as levothyroxine, warfarin, ciclosporin and antiepileptics are handled cautiously (Section 13.2).

Adherence is an economic intervention. A medicine that is not taken delivers zero effect at full cost, so counselling that converts a non-adherent patient into an adherent one improves cost-effectiveness more reliably than switching molecules.

Avoided costs are the argument. When justifying a therapy to a payer, the persuasive figure is rarely the drug price - it is the admission, the bleed, the amputation, or the exacerbation that does not happen.

Cheapest is not the same as most cost-effective. A low-acquisition-cost drug that requires frequent monitoring, causes more adverse events, or is poorly tolerated can carry the higher total cost of care.